Cyprotex US LLC
Framingham, MA
- UEI
- YNGLSAF57T14
- CAGE
- 47UC6
- Primary NAICS
- 541380 Testing Laboratories and Services
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 200 Staples Dr, Framingham, MA 01702, USA
- Website
- evotec.com
- Founded
- 1993
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $49,812 |
| FY2025 | $495,620 |
| FY2024 | $397,116 |
| FY2023 | $281,491 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $49,812 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Cyprotex US LLC, a foreign-owned contract research organization based in Framingham, Massachusetts, provides specialized in vitro toxicology testing and absorption, distribution, metabolism, excretion, and toxicity (ADMET) characterization services to federal regulatory and research agencies as a prime contractor exclusively—with no subcontract footprint. The vendor competes full-and-open with no SBA set-aside designation across all federal work.
Cyprotex's capability portfolio centers on predictive toxicology, high-throughput toxicokinetics (HTTK), cytochrome P450 inhibition assays, Caco-2 permeability assessments, hepatocyte stability testing, plasma protein binding assays, and chemical risk assessment through in vitro methodology. The vendor characterizes small-molecule drug candidates and industrial chemical compounds to support pharmaceutical development and environmental protection missions. Representative work includes a $451,818 delivery order from the EPA Office of Research and Development for HTTK testing (Task Order #7 under a $13 million single-award IDIQ established in May 2020), a $157,158 purchase order from the National Cancer Institute for ADMET characterization of drug candidates under the Developmental Therapeutics Program, and a $70,500 purchase order from the Food and Drug Administration (awarded September 2026) for development of a human neural network formation method to evaluate potential developmental neurotoxicity.
The EPA Office of Research and Development dominates Cyprotex's customer base, accounting for 25 awards and $162.6 million in combined potential value—roughly 99% of the vendor's total federal pipeline. The remaining customer concentration is fragmented across NIH institutes: the National Institute on Drug Abuse (11 awards, $638 thousand), the National Center for Advancing Translational Sciences (9 awards, $363 thousand), the National Cancer Institute (2 awards, $213 thousand), and the National Institute of Neurological Disorders and Stroke (1 award). Cyprotex's vehicle position rests on three EPA IDIQ contracts: EPD11082 (11 task orders, $6.5 million combined potential value), 140D0420D0003 (7 task orders, $2.9 million), and EPD13013 (3 task orders, $436 thousand).
Activity trajectory has flattened sharply. The vendor received seven awards in 2022, six in 2023, and only two in 2024 and one in 2025, with one award in 2026. The recompete cliff presents minimal exposure—only one award with ultimate completion in the next twenty-four months carries $71 thousand in combined potential value. Across 57 total prime awards, combined potential value stands at $164.9 million against $11.3 million in obligated dollars (7% liquidation), indicating substantial award backlog or long-tail performance periods. The vendor's award history spans fifteen years, with work classified primarily under NAICS 541380 (Testing Laboratories and Services) and 541711 (Research and Development in Physical, Engineering, and Life Sciences), anchored to PSC codes for Reference Laboratory Testing and R&D in Environmental Sciences.
Quick answers
Is Cyprotex US LLC registered in SAM.gov?
Yes. Cyprotex US LLC's SAM.gov registration is active through May 27, 2027.
How much has Cyprotex US LLC received in federal contracts?
Federal contracts obligated $495,620 to Cyprotex US LLC in fiscal year 2025 and $1,224,039 in fiscal years 2023 through 2027.
How does Cyprotex US LLC rank among federal contractors?
Cyprotex US LLC ranked #15 in PSC B504 in FY2025.
What is Cyprotex US LLC's most recent federal award?
Cyprotex US LLC's most recent federal contract award is EO 14398 - purchase of development of a human neural network formation new approach method for the evaluation of… (75F40126P00176), from Food and Drug Administration, on September 1, 2026.
On GovTribe
See Cyprotex US LLC's full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors